FCGR2B and neoplasm: However, combined treatment with anti-Gr-1 neutralizing antibody and FcγRIIB antagonistic antibody did not induce further reduction of tumor volume and tumor-infiltrating MDSCs compared with mice treated with FcγRIIB antagonistic antibody alone (Figures S6A and S6B).